Rogers Eamonn T, Bognanno Thomas G, Perkins Thomas, Wolf Gianares Brittany, Schuler Kristine W, Geissler Jan, Larsen Vivian, Lobban Dawn, Dormer Laura E, Daly Jacqueline, Scott Jessica, Efstathiou Eleni
Department of Urology, University College Hospital Galway, Galway, Ireland.
Patient Office, European Association of Urology, Arnhem, Netherlands.
Future Oncol. 2025 Jun 11:1-10. doi: 10.1080/14796694.2025.2514415.
Barriers preventing oncologists from engaging patients as research partners remain. This study aimed to understand oncologists' barriers to patient engagement and involvement (PEI) in research and identify solutions to overcome barriers.
The study consisted of three phases: I, insights research ( = 6); II, qualitative research ( = 30); III, a Working Group of PEI experts providing recommendations ( = 10). Five hypotheses representing oncologists' barriers to PEI identified in phase I were tested in phase II: A) preference for physician-led approach to medicine; B) limited PEI value in research processes; C) misconceptions about approaching PEI; D) practical barriers to PEI; E) traditional research dynamics preventing PEI.
Hypotheses C, D, and E were identified as the most critical and ranked in descending order of difficulty to overcome (D, E, and C). Solutions were ranked according to importance (whether oncologists perceived barriers as prominent within their communities) and feasibility (for stakeholders to find solutions). Solutions included leveraging institutional PEI teams, allocating funding for PEI, practical/logistical support for patient research partners, incentivising PEI, facilitating training, creating a patient research partner directory, and PEI guidelines.
Enhanced support for oncologists and institutional incentives to encourage PEI in all aspects of research are required.
阻碍肿瘤学家让患者成为研究伙伴的障碍依然存在。本研究旨在了解肿瘤学家在患者参与研究方面的障碍，并确定克服这些障碍的解决方案。
该研究包括三个阶段：第一阶段，见解研究（n = 6）；第二阶段，定性研究（n = 30）；第三阶段，患者参与研究专家工作组提供建议（n = 10）。在第一阶段确定的代表肿瘤学家在患者参与研究方面障碍的五个假设在第二阶段进行了检验：A）倾向于以医生为主导的医疗方法；B）在研究过程中患者参与研究的价值有限；C）对患者参与研究的误解；D）患者参与研究的实际障碍；E）传统研究模式阻碍患者参与研究。
假设C、D和E被确定为最关键的，按克服难度从高到低排序（D、E、C）。解决方案根据重要性（肿瘤学家是否认为障碍在其所在领域中突出）和可行性（利益相关者能否找到解决方案）进行排序。解决方案包括利用机构患者参与研究团队、为患者参与研究分配资金、为患者研究伙伴提供实际/后勤支持、激励患者参与研究、促进培训、创建患者研究伙伴名录以及制定患者参与研究指南。
需要加强对肿瘤学家的支持，并通过机构激励措施鼓励在研究的各个方面实现患者参与研究。
